Q1(24) i korthet Nettoomsättningen under Q1(24) uppgick till 9 mkr (13) och rörelseresultatet uppgic...
Fortsatt stark orderingång men ett på resultatnivå säsongsmässigt svagt kvartal Sensys Gatso leverer...
Redeye offers an update on Advenica following the company's Q1 report.
Doro delivered a soft topline growth but a large part of the softness was due to one-offs.
Full-year revenue and EBIDA guidance from the company remains intact but we lower our 2024 EBITDA fo...
Increased estimates on higher oil price assumptions Exciting exploration activities ahead P/NAV of 0...
Redeye retains its optimistic view on Hexatronic despite slightly lowering its Base Case and short-t...
Redeye raises its Base Case and forecasts somewhat following a solid Q1 report, beating our expectat...
Adj. EBITA in line, we expect higher margins ahead Minor revisions: adj.
Q1 a seasonally small quarter, adj. EBITA of EUR -4m Margin lift from Q2e following recent divestmen...
Redeye repeats its view on Sedana Medical’s 2024 sales growth target to be conservative, as is demon...
Through the completion of the equity issue, Lytix receives NOK50m before transaction costs.
- '24e sales up 2% - New ARR shows sequential growth stability - '24e-'25e EV/EBITDA ~11-9x Another ...
AcuCort har publicerat bolagets delårsrapport för det första kvartalet 2024.
AVTECH’s net sales and EBITDA were below Redeye Research estimates (RRe), but the company managed to...
Net sales was 3% above Nordea’s estimate in Q1. The company’s EBITDA was EUR 4.
Redeye states that the report aligns with preannounced figures and is slightly below RRe on net sale...
Redeye leaves a comment following today’s announcement of a rights issue of approximately SEK34.
Mangold Insight inleder bevakning av medicinteknik-bolaget Prolight Diagnostics med rekommendationen...
Hyresmarknaden förbättrades under kvartalet, vilket spelar Fastpartner rakt i händerna.
